SG11202113330VA - Bicyclic compound as rip-1 kinase inhibitor and application thereof - Google Patents
Bicyclic compound as rip-1 kinase inhibitor and application thereofInfo
- Publication number
- SG11202113330VA SG11202113330VA SG11202113330VA SG11202113330VA SG11202113330VA SG 11202113330V A SG11202113330V A SG 11202113330VA SG 11202113330V A SG11202113330V A SG 11202113330VA SG 11202113330V A SG11202113330V A SG 11202113330VA SG 11202113330V A SG11202113330V A SG 11202113330VA
- Authority
- SG
- Singapore
- Prior art keywords
- rip
- application
- kinase inhibitor
- bicyclic compound
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910471672 | 2019-05-31 | ||
| CN201911089490 | 2019-11-08 | ||
| CN202010432710 | 2020-05-20 | ||
| PCT/CN2020/093280 WO2020239074A1 (fr) | 2019-05-31 | 2020-05-29 | Composé bicyclique en tant qu'inhibiteur de la kinase rip-1 et son application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202113330VA true SG11202113330VA (en) | 2021-12-30 |
Family
ID=73553496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202113330VA SG11202113330VA (en) | 2019-05-31 | 2020-05-29 | Bicyclic compound as rip-1 kinase inhibitor and application thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220242877A1 (fr) |
| EP (1) | EP3978492A4 (fr) |
| JP (1) | JP7299350B2 (fr) |
| KR (1) | KR20220016223A (fr) |
| CN (1) | CN114008038B (fr) |
| AU (1) | AU2020285269B2 (fr) |
| BR (1) | BR112021024116A2 (fr) |
| CA (1) | CA3142360C (fr) |
| SG (1) | SG11202113330VA (fr) |
| WO (1) | WO2020239074A1 (fr) |
| ZA (1) | ZA202110347B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| CN112778291B (zh) * | 2021-01-27 | 2023-02-28 | 中国人民解放军海军军医大学 | 一种硫代七元环类衍生物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU681924B2 (en) * | 1993-11-22 | 1997-09-11 | Merck & Co., Inc. | 3-acylaminobenzazepines |
| WO1999015524A1 (fr) * | 1997-09-23 | 1999-04-01 | Fujisawa Pharmaceutical Co., Ltd. | Derives de thiazole |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| AR079170A1 (es) * | 2009-12-10 | 2011-12-28 | Lilly Co Eli | Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par |
| TWI638815B (zh) * | 2013-02-15 | 2018-10-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（一） |
| CN104418866B (zh) * | 2013-08-23 | 2018-10-16 | 青岛黄海制药有限责任公司 | Dgat1抑制剂及其制备方法和用途 |
| CA2988601C (fr) * | 2015-07-02 | 2021-12-07 | F. Hoffmann-La Roche Ag | Lactames bicycliques et leurs methodes d'utilisation |
| EA201891620A1 (ru) * | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
-
2020
- 2020-05-29 KR KR1020217043320A patent/KR20220016223A/ko not_active Application Discontinuation
- 2020-05-29 WO PCT/CN2020/093280 patent/WO2020239074A1/fr unknown
- 2020-05-29 EP EP20814764.5A patent/EP3978492A4/fr active Pending
- 2020-05-29 AU AU2020285269A patent/AU2020285269B2/en active Active
- 2020-05-29 CA CA3142360A patent/CA3142360C/fr active Active
- 2020-05-29 BR BR112021024116A patent/BR112021024116A2/pt unknown
- 2020-05-29 SG SG11202113330VA patent/SG11202113330VA/en unknown
- 2020-05-29 JP JP2021571444A patent/JP7299350B2/ja active Active
- 2020-05-29 CN CN202080040268.1A patent/CN114008038B/zh active Active
- 2020-05-29 US US17/614,939 patent/US20220242877A1/en active Pending
-
2021
- 2021-12-13 ZA ZA2021/10347A patent/ZA202110347B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021024116A2 (pt) | 2022-01-11 |
| AU2020285269A1 (en) | 2022-01-06 |
| CA3142360A1 (fr) | 2020-12-03 |
| CN114008038A (zh) | 2022-02-01 |
| EP3978492A1 (fr) | 2022-04-06 |
| US20220242877A1 (en) | 2022-08-04 |
| AU2020285269B2 (en) | 2022-11-17 |
| JP7299350B2 (ja) | 2023-06-27 |
| EP3978492A4 (fr) | 2023-06-28 |
| KR20220016223A (ko) | 2022-02-08 |
| WO2020239074A1 (fr) | 2020-12-03 |
| ZA202110347B (en) | 2022-06-29 |
| JP2022535794A (ja) | 2022-08-10 |
| CN114008038B (zh) | 2023-01-24 |
| CA3142360C (fr) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202000395B (en) | Aryl-phosphorus-oxygen compound as egfr kinase inhibitor | |
| IL285823A (en) | Bicyclic heteroaryl compounds and their uses | |
| IL292679A (en) | Cyclic heteroaryl compounds and their uses | |
| IL289534A (en) | Inhibitors of parp1 | |
| EP3293177A4 (fr) | Inhibiteur de la tyrosine kinase et composition pharmaceutique le comprenant | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| EP4079735A4 (fr) | Composé pour inhiber et induire la dégradation de la kinase egfr | |
| EP3974422A4 (fr) | Composé utilisé comme inhibiteur de kinase ret et son utilisation | |
| EP3804707A4 (fr) | Inhibiteur de kinase | |
| EP3768267A4 (fr) | Composés inhibiteurs de kinase, compositions et procédés d'utilisation | |
| ZA202109737B (en) | Compound used as kinase inhibitor and application thereof | |
| ZA202110347B (en) | Bicyclic compound as rip-1 kinase inhibitor and application thereof | |
| ZA202105752B (en) | Haloallylamine compounds and application thereof | |
| EP3906233A4 (fr) | Composés inhibiteurs de kinase, compositions et procédés d'utilisation | |
| EP3906028A4 (fr) | Composés inhibiteurs de kinase, compositions et méthodes d'utilisation | |
| EP4074699A4 (fr) | Composé utile en tant qu'inhibiteur de la kinase 9 dépendante de la cycline et son utilisation | |
| SG11202008705TA (en) | Heteroaryl compounds as kinase inhibitor | |
| EP3630113A4 (fr) | Composition pharmaceutique comprenant un inhibiteur de pde9 | |
| IL308476A (en) | Inhibitors of the menin-mil interaction | |
| IL269144A (en) | Pyrrolotriazine derivatives as kinase inhibitors | |
| EP3717475A4 (fr) | Composés inhibiteurs de kinase, compositions et procédés d'utilisation | |
| EP3284746A4 (fr) | Préparation et utilisation d'un inhibiteur de kinase | |
| FI4196479T3 (fi) | Substituoituja pyridotriatsiiniyhdisteitä ja niiden käyttöjä | |
| IL287316A (en) | compounds and preparations | |
| EP4155304A4 (fr) | Composé utilisé comme inhibiteur de kinase ret et son application |